CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers

被引:0
作者
L Kadouri
D F Easton
S Edwards
A Hubert
Z Kote-Jarai
B Glaser
F Durocher
D Abeliovich
T Peretz
R A Eeles
机构
[1] Sharett Institute of Oncology,Department of Endocrinology and Metabolism
[2] Hebrew University-Hadassah Medical Center,undefined
[3] CRC Section of Cancer Genetics,undefined
[4] The Institute of Cancer Research,undefined
[5] CRC Genetic Epidemiology Unit,undefined
[6] Strangeways Research Laboratories,undefined
[7] Hebrew University-Hadassah Medical Center,undefined
[8] Human Genetic Laboratories,undefined
[9] Hebrew University-Hadassah Medical Center,undefined
[10] The Royal Marsden NHS Trust,undefined
来源
British Journal of Cancer | 2001年 / 85卷
关键词
androgen receptor; polymorphisms; breast cancer risk;
D O I
暂无
中图分类号
学科分类号
摘要
Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased risk of breast cancer (BC). We genotyped 188 BRCA1/2 carriers (122 affected and 66 unaffected with breast cancer), 158 of them of Ashkenazi origin, 166 BC cases without BRCA1/2 mutations and 156 Ashkenazi control individuals aged over 56 for the AR CAG and GGC repeats. In carriers, risk analyses were conducted using a variant of the log-rank test, assuming two sets of risk estimates in carriers: penetrance estimates based on the Breast Cancer Linkage Consortium (BCLC) studies of multiple case families, and lower estimates as suggested by population-based studies. We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population. Assuming BRCA1/2 penetrance estimates appropriate to the Ashkenazi population, the estimated RR per repeat adjusted for ethnic group (Ashkenazi and non-Ashkenazi) was 1.05 (95%CI 0.97–1.17) for BC and 1.00 (95%CI 0.83–1.20) for ovarian cancer (OC) for CAG repeats and 0.96 (95%CI 0.80–1.15) and 0.90 (95%CI 0.60–1.22) respectively for GGC repeats. The corresponding RR estimates for the unselected case–control series were 1.00 (95%CI 0.91–1.10) for the CAG and 1.05 (95%CI 0.90–1.22) for the GGC repeats. The estimated relative risk of BC in carriers associated with ≥28 CAG repeats was 1.08 (95%CI 0.45–2.61). Furthermore, no significant association was found if attention was restricted to the Ashkenazi carriers, or only to BRCA1 or BRCA2 carriers. We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak. © 2001 Cancer Research Campaign http://www.bjcancer.com
引用
收藏
页码:36 / 40
页数:4
相关论文
共 50 条
  • [21] The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40
    Elhaji, YA
    Gottlieb, B
    Lumbroso, R
    Beitel, LK
    Foulkes, WD
    Pinsky, L
    Trifiro, MA
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 70 (02) : 109 - 116
  • [22] Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations
    Pristauz, Gunda
    Petru, Edgar
    Stacher, Elvira
    Geigl, Jochen B.
    Schwarzbraun, Thomas
    Tsybrovskyy, Oleksiy
    Winter, Raimund
    Moinfar, Farid
    HISTOPATHOLOGY, 2010, 57 (06) : 877 - 884
  • [23] Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations:: A meta-analytic approach
    Fu, Rongwei
    Harris, Emily L.
    Helfand, Mark
    Nelson, Heidi D.
    STATISTICS IN MEDICINE, 2007, 26 (08) : 1775 - 1787
  • [24] Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
    KA Phillips
    RL Milne
    MA Rookus
    D Goldgar
    M Friedlander
    SA McLachlan
    S Buys
    AC Antoniou
    K Birch
    MB Terry
    DF Easton
    P Weideman
    M Daly
    N Andrieu
    EM John
    MJ Hooning
    IL Andrulis
    T Caldes
    H Olsson
    JL Hopper
    Hereditary Cancer in Clinical Practice, 10 (Suppl 2)
  • [25] Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility
    Wu, Mei-Hsuan
    Chou, Yu-Ching
    Yu, Cheng-Pung
    Yang, Tsan
    You, San-Lin
    Chen, Chien-Jen
    Sun, Chien-An
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2008, 17 (04) : 317 - 322
  • [26] Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers
    Benitez-Buelga, Carlos
    Vaclova, Tereza
    Ferreira, Sofia
    Urioste, Miguel
    Inglada-Perez, Lucia
    Soberon, Nora
    Blasco, Maria A.
    Osorio, Ana
    Benitez, Javier
    ONCOTARGET, 2016, 7 (18) : 25815 - 25825
  • [28] Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years
    Whittemore A.S.
    John E.M.
    Felberg A.
    McGuire V.
    West D.W.
    Miron A.
    Thomas D.C.
    Haile R.
    Daly M.
    Godwin A.
    Ross E.
    Beck J.
    Terry M.B.
    Buys S.S.
    Venne V.
    Hopper J.L.
    Giles G.G.
    McCredie M.R.E.
    Milne R.L.
    Southey M.C.
    Jenkins M.A.
    Apicella C.
    Andrulis I.
    Boyd N.F.
    Knight J.
    Ozcelik H.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (01) : 67 - 75
  • [29] Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
    Osorio, A.
    Milne, R. L.
    Alonso, R.
    Pita, G.
    Peterlongo, P.
    Teule, A.
    Nathanson, K. L.
    Domchek, S. M.
    Rebbeck, T.
    Lasa, A.
    Konstantopoulou, I.
    Hogervorst, F. B.
    Verhoef, S.
    van Dooren, M. F.
    Jager, A.
    Ausems, M. G. E. M.
    Aalfs, C. M.
    van Asperen, C. J.
    Vreeswijk, M.
    Waisfisz, Q.
    Van Roozendaal, C. E.
    Ligtenberg, M. J.
    Easton, D. F.
    Peock, S.
    Cook, M.
    Oliver, C. T.
    Frost, D.
    Curzon, B.
    Evans, D. G.
    Lalloo, F.
    Eeles, R.
    Izatt, L.
    Davidson, R.
    Adlard, J.
    Eccles, D.
    Ong, K-R
    Douglas, F.
    Downing, S.
    Brewer, C.
    Walker, L.
    Nevanlinna, H.
    Aittomaki, K.
    Couch, F. J.
    Fredericksen, Z.
    Lindor, N. M.
    Godwin, A.
    Isaacs, C.
    Caligo, M. A.
    Loman, N.
    Jernstrom, H.
    BRITISH JOURNAL OF CANCER, 2011, 104 (08) : 1356 - 1361
  • [30] Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations
    Khoury-Shakour, Sana
    Lejbkowicz, Flavio
    Barnett-Griness, Ofra
    Tamir, Ada
    Pinchev, Mila
    Rennert, Gad
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2009, 18 (05) : 361 - 367